GREB1抗体;GREB1 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P11805(GREB1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P11805(GREB1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The GREB1 (Growth Regulation by Estrogen in Breast Cancer 1) antibody is a tool used to detect and study the GREB1 protein, a key player in estrogen-regulated pathways. GREB1 was initially identified as an estrogen-responsive gene in breast cancer cells, functioning as a mediator of estrogen receptor alpha (ERα) signaling. It is involved in hormone-dependent growth and proliferation of tissues, particularly in breast and ovarian cancers. GREB1 expression correlates with ERα status, making it a biomarker for hormone-responsive cancers and a potential therapeutic target.

Antibodies targeting GREB1 enable researchers to investigate its expression patterns, subcellular localization (primarily nuclear), and interactions with ERα in cancer models. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess GREB1 levels in clinical samples or cell lines. Commercially available GREB1 antibodies are typically monoclonal or polyclonal, validated for specificity across human and rodent tissues.

Studies using GREB1 antibodies have highlighted its role in tumor progression, metastasis, and treatment resistance. Elevated GREB1 levels are associated with poor prognosis in ER-positive breast cancers, underscoring its clinical relevance. Additionally, research explores GREB1's non-canonical functions in development and non-hormonal cancers. As interest in personalized oncology grows, GREB1 antibodies remain critical for deciphering hormonal signaling mechanisms and advancing targeted therapies.